Spinal muscular atrophy (SMA) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Spinal muscular atrophy (SMA) is a group of inherited disorders characterized by a loss of certain nerve cells in the spinal cord called motor neurons or anterior horn cells. Etiology- SMA types 0, 1, 2, 3, and 4 are inherited as autosomal recessive genetic disorders and are associated with abnormalities (mutations) in the SMN1 and SMA2 genes on chromosome 5 at chromosomal locus 5q11-q13. SMA1 is thought to be the primary disease-causing gene. Epidemiology- Spinal muscular atrophy affects 1 per 8,000 to 10,000 people worldwide. The competitive landscape of Spinal muscular atrophy (SMA) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary. KOLs insights of Spinal muscular atrophy (SMA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment land...